The increased cellular level of TG2 contributes to the development of drug resistance and metastatic phenotype in several cancer cell types such as that of pancreatic cancer [12], ovarian cancer cells [13,14], breast cancer [15], glioblastoma and malignant melanoma [16]. This evidence concerns the gene TGM2 and pancreatic neoplasm.